| Characteristics | 0.003 group (n = 12) | 0.006 group (n = 12) | p Value |
| Age (years) | 59 (3) | 58 (4) | 0.772 |
| Male, n (%) | 9 (75) | 6 (50) | 0.400 |
| Body mass index (kg/m2) | 30 (1) | 34 (2) | 0.260 |
| Body surface area (m2) | 2 (0.1) | 2 (0.1) | 0.954 |
| PTCA/thrombolytic agents | 12:0 | 11:1 | 1.000 |
| Hypertension, n (%) | 5 (42) | 6 (50) | 1.000 |
| Diabetes, n (%) | 3 (25) | 0 (0) | 0.214 |
| Time to reperfusion (min) | 321 (72) | 253 (75) | 0.214 |
| Creatine kinase-MB peak (ng/ml) | 217 (80) | 212 (50) | 0.926 |
| Systolic blood pressure (mm Hg) | 127 (5) | 125 (8) | 0.544 |
| Diastolic blood pressure (mm Hg) | 76 (4) | 78 (6) | 0.707 |
| LV ejection fraction (%) | 42 (2) (n = 11) | 40 (4) (n = 10) | 0.972 |
| LV end-systolic volume (ml/m2) | 60 (11) (n = 10) | 61 (9) (n = 9) | 1.000 |
| LV end-diastolic volume (ml/m2) | 104 (18) (n = 10) | 96 (11) (n = 9) | 0.939 |
| ACEI or ARB, n (%) | 1 (8) | 2 (17) | 1.000 |
| β Blocker, n (%) | 3 (25) | 2 (17) | 1.000 |
Results are shown as mean (SEM) unless stated otherwise.
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; LV, left ventricular; PTCA, percutaneous transluminal coronary angioplasty.